Cover Image

HARDBACK
$52.95



View/Hide Left Panel

Table A16–2 Disease Scenarios for TB Infection

 

No. of Cases

% of Cases

Committee HUI Values

Duration (years)

Total Deaths (from acute infection)

1,476

 

Total Cases (reported)

22,795

 

Asymptomatic—suspect

suspect cases (treatment begun)

68,385

300.00%

1.0000

0.2500 (3 months)

Asymptomatic—latent infection

preventive treatment for latent infection

113,975

500.00%

1.0000

0.5000 (6 months)

Pulmonary TB

inpatient

20,060

88.00%

0.8700

0.0548 (20 days)

Pulmonary TB

outpatient

19,057

83.60%

0.8900

0.7500 (9 months)

Extrapulmonary TB

inpatient

2,735

12.00%

0.7200

0.0548 (20 days)

Extrapulmonary TB

outpatient

2,462

10.80%

0.8600

0.7500 (9 months)

60% of the targeted population in multi-drug-resistant areas would receive the vaccine.

Vaccine Schedule, Efficacy, and Costs

For the purposes of the calculations in this report, it was estimated that this vaccine would cost $50 per dose and that administration costs would be $10 per dose. Default assumptions of a 3-dose series and 75% effectiveness were accepted. Table 4–1 summarizes vaccine program assumptions for all vaccines considered in this report.

RESULTS

If a vaccine program for TB were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the QALYs gained would be $4,000. Using committee assumptions of less-than-ideal efficacy and utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the QALYs gained would be 1,300.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement